micafungin + Micafungin + Caspofungin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Candidemia
Conditions
Candidemia
Trial Timeline
Dec 1, 2008 → May 1, 2010
NCT ID
NCT00839540About micafungin + Micafungin + Caspofungin
micafungin + Micafungin + Caspofungin is a approved stage product being developed by Astellas Pharma for Candidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00839540. Target conditions include Candidemia.
What happened to similar drugs?
3 of 7 similar drugs in Candidemia were approved
Approved (3) Terminated (2) Active (3)
🔄Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + PlaceboBasilea PharmaceuticaPhase 3
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00839540 | Approved | Completed |
Competing Products
9 competing products in Candidemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Approved | 35 |
| AmBisome | Gilead Sciences | Approved | 43 |
| Anidulafungin/Fluconazole | Pfizer | Phase 3 | 32 |
| Anidulafungin + Voriconazole | Pfizer | Approved | 43 |
| Anidulafungin + Fluconazole | Pfizer | Phase 3 | 40 |
| Anidulafungin | Pfizer | Phase 3 | 40 |
| Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + Placebo | Basilea Pharmaceutica | Phase 3 | 41 |
| APX001 | Basilea Pharmaceutica | Phase 2 | 29 |
| APX001 | Basilea Pharmaceutica | Phase 2 | 29 |